ABSTRACT
Hydralazine (Apresoline) is a direct-acting vasodilator with an onset of action of 3-20 min following IV administration, and a duration of action of 2-6 h. It is the drug of choice in eclampsia as it preserves myometrial blood flow. Hydralazine is relatively contraindicated as the sole antihypertensive agent in patients with severe coronary disease, because of the potential for precipitating reflex tachycardia. In addition, hydralazine has been reported to cause a lupus-like rash, fluid retention and headache. Typical IV doses of hydralazine are 5-10 mg q 4-6 h individualized to the patient’s response. Oral doses are 10-50 mg p.o. q 6 h.
